Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
弗吉尼亚州夏洛茨维尔，9月2023年05日(环球通讯社)--ADIAL制药公司(纳斯达克代码：ADIL；ADILW)(“ADIAL”或“公司”)，一家临床阶段的生物制药公司专注于开发治疗和预防成瘾及相关疾病的疗法，该公司今天宣布，Aial制药公司的首席执行官卡里·克莱本将参加H.C.温赖特25这是一年一度的全球投资大会将于2023年9月11日至13日在纽约市乐天纽约皇宫酒店举行。
Adial's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 11, 2023 at 7:00 AM Eastern Time. A webcast of the Company's presentation can also be accessed at and on the investor relations section of company Adial's website at
从2023年9月11日(星期一)东部时间上午7：00开始，ADIAL将通过会议平台向注册与会者提供ADIAL的演示文稿。还可以通过公司Aial网站的投资者关系部分收看公司演示文稿的网络直播，网址为
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact adil@crescendo-ir.com.
在纽约举行的整个会议期间，管理层将参加与合格投资者群体成员的一对一会议。如需预约，请联系adil@cresendo-ir.com。
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at .
关于阿迪尔制药公司
ADIAL制药公司是一家临床阶段的生物制药公司，专注于开发成瘾和相关疾病的治疗方法。该公司领先的研究新药产品AD04是一种基因靶向的5-羟色胺-3受体拮抗剂，是用于治疗酗酒患者酒精使用障碍(AUD)的治疗剂，最近在该公司未来关键的第三阶段临床试验中使用该公司的配套诊断基因测试对某些目标基因类型(估计约占AUD人群的三分之一)的患者治疗AUD的可能性进行了研究。进一步的研究显示，在减少重度饮酒患者饮酒方面取得了有希望的结果，没有明显的安全性或耐受性问题。AD04还被认为有可能治疗其他成瘾性疾病，如阿片类药物使用障碍、赌博和肥胖。欲了解更多信息，请访问。
Contact:
联系方式：
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
Cresendo Communications，LLC
大卫·沃尔德曼/亚历山德拉·希尔特
电话：212-671-1020
电子邮件：adil@cresendo-ir.com